Jindrich Kopecky
Overview
Explore the profile of Jindrich Kopecky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
304
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Incorvaia L, Scagliarini S, Marques Monteiro F, Takeshita H, Tapia J, Gandur Quiroga M, et al.
Sci Rep
. 2025 Mar;
15(1):8815.
PMID: 40087324
Gender- and sex-based disparities in response to immune-checkpoint inhibitors (ICI) has been reported in a variety of tumor types. Women have different anatomy with recurrent urinary tract infections, a different...
2.
Fiala O, Buti S, Fujita K, de Liano A, Fukuokaya W, Kimura T, et al.
Clin Exp Metastasis
. 2025 Feb;
42(2):18.
PMID: 39976819
Patients with metastatic urothelial carcinoma (mUC) are typically elderly and often have other comorbidities that require the use of concomitant medications. In our study we evaluated the association of concomitant...
3.
Pasek M, Kopecky J, Tretera V, Arenberger P, Arenbergerova M
J Eur Acad Dermatol Venereol
. 2024 Sep;
PMID: 39258869
No abstract available.
4.
Incorvaia L, Marques Monteiro F, Massari F, Park S, Roviello G, Fiala O, et al.
Cancer Immunol Immunother
. 2024 Jun;
73(8):142.
PMID: 38832989
Background: There is an ongoing debate as to whether sex could be associated with immune checkpoint inhibitor (ICI) benefit. Existing literature data reveal contradictory results, and data on first-line immune...
5.
Fiala O, Buti S, Bamias A, Massari F, Pichler R, Maruzzo M, et al.
Target Oncol
. 2024 May;
19(4):587-599.
PMID: 38704759
Background: About 20% of patients with renal cell carcinoma present with non-clear cell histology (nccRCC), encompassing various histological types. While surgery remains pivotal for localized-stage nccRCC, the role of cytoreductive...
6.
Massari F, Santoni M, Takeshita H, Okada Y, Tapia J, Basso U, et al.
Cancer Immunol Immunother
. 2024 Apr;
73(6):106.
PMID: 38634928
Background: Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness of pembrolizumab in patients recurred or...
7.
Kopecky J, Pasek M, Lakomy R, Melichar B, Mrazova I, Kubecek O, et al.
Cancer Med
. 2024 Mar;
13(5):e6982.
PMID: 38491825
Background: Immunotherapy and targeted therapy are currently two alternative backbones in the therapy of BRAF-mutated malignant melanoma. However, predictive biomarkers that would help with treatment selection are lacking. Methods: This...
8.
Marques Monteiro F, Fiala O, Massari F, Myint Z, Kopecky J, Kucharz J, et al.
Clin Genitourin Cancer
. 2023 Dec;
22(2):305-314.e3.
PMID: 38087702
Background: Systemic treatment with immune combinations is the gold standard for metastatic renal cell carcinoma (mRCC) worldwide. The systemic immune-inflammation index (SII) is a prognostic marker for several types of...
9.
Poprach A, Kiss I, Stanik M, Barusova T, Pospisilova L, Fiala O, et al.
Target Oncol
. 2023 Nov;
18(6):893-903.
PMID: 37957520
Background: Treatment options for metastatic renal cell carcinoma (mRCC) are rapidly expanding, and immunotherapy using checkpoint inhibitors is a first- or second-line option for most patients. Objective: The objective of...
10.
Santoni M, Massari F, Takeshita H, Tapia J, Dionese M, Pichler R, et al.
Clin Exp Med
. 2023 Nov;
23(8):5413-5422.
PMID: 37917218
The ARON-2 study (NCT05290038) aimed to assess the real-world efficacy of pembrolizumab in patients recurred or progressed after platinum-based chemotherapy. This retrospective analysis reports the outcomes of urothelial carcinoma (UC)...